India, Oct. 29 -- Pulmonx Corporation (LUNG), on Wednesday reported third-quarter 2026 worldwide revenue of $22.8 million, up 6% from $21.5 million in the year-ago quarter, as the company returned to year-over-year revenue growth.
The medical device company also reduced its net loss and adjusted EBITDA loss, supported by lower operating expenses following cost realignment efforts.
For the quarter ended September 30, 2026, Pulmonx reported net loss of $8.4 million, or $0.19 per share, compared with a net loss of $14.0 million, or $0.34 per share, in the prior-year quarter.
Gross profit increased to $17.4 million from $16.1 million, while gross margin improved to 76% from 75%.
Operating expenses declined 18% to $24.9 million from $30.4 mi...